Journal article
Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers
JA Westwood, GM Matthews, J Shortt, D Faulkner, HJ Pegram, CPM Duong, M Chesi, PL Bergsagel, LL Sharp, RD Huhn, PK Darcy, RW Johnstone, MH Kershaw
Leukemia Research | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2014
Abstract
In order to stimulate antigen presentation and T cell activity against cancer, we treated three different tumor models in mice with the monoclonal antibodies anti-CD40 plus anti-CD137 (BiMab). In a subcutaneous transplantable MC38 colon cancer model, there was significant enhancement in the survival of mice following BiMab treatment. Anti-CD40 has shown considerable success against lymphoma in previous studies by other investigators, and we also showed in this study that, in a model of Eμ-Myc lymphoma, there was a statistically significant enhancement of survival of mice following BiMab treatment. Following the success of the BiMab treatment in the previous two models, we wished to determine..
View full abstractGrants
Awarded by Pfizer
Funding Acknowledgements
MK, PD and JW funded by National Health & Medical Research Council of Australia (NHMRC) Project Grant. MK and PD are supported by Senior Research Fellowships from NHMRC and Grant # 1066554 from the Cancer Council of Victoria. Some of the work was funded by Pfizer, San Diego, CA.